Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

NCT02611817 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

644

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Vedolizumab SC 108 mg
DRUG: Placebo
DRUG: Vedolizumab IV 300 mg

Sponsor

Takeda